MMMichele Malagola

Michele Malagola

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michele Malagola has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients

    by Michele Malagola, Cristina Skert, Marco Vignetti, Alfonso Piciocchi, Giovanni Martinelli, Giuliana Alimena, Cristina Mecucci, Nicoletta Testoni, Ilaria Iacobucci, Marino Clavio, et al.

    We retrospectively analyzed the data of 337 patients with cytogenetically normal (CN) acute myeloid leukemia (AML), aged ≤ 65 years (training set). A prognostic index score (PIS) was calculated by totaling the score derived from the regression coefficients of each clinical variable, significantly associated with prognosis by multivariate analysis. The variables that were independent prognostic factors for event-free survival (EFS) and overall survival (OS) in the training set were: age ≥ 50 years, secondary AML and white blood cell count (WBC) ≥ 20 × 109/L. The patients of the training set were stratified into three groups: low-, intermediate- and high-risk. The median EFS was 25, 12 and 7 months in the low-, intermediate- and high-risk groups (p < 0.0001), respectively. The median OS was not reached in the low-risk group and was 19 and 10 months in the intermediate- and high-risk groups (p < 0.0001). This PIS was validated in a series of 193 patients with CN-AML. The median EFS was 66, 16, and 3 months (p < 0.0001) and the median OS was 66, 16, and 5 months in the three risk groups, respectively (p < 0.0001). This PIS may be useful for clinical decision-making in CN-AML and may be prospectively integrated with the newest biological markers which at present are not routinely assessed and need prognostic validation.


  • Low Dose Ara-C for Myelodysplastic Syndromes: is it Still a Current Therapy?

    by Giuseppe Visani, Michele Malagola, Pier Paolo Piccaluga, Alessandro Isidori

    The myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency associated with severe cytopenias, leading to serious morbidity, and acute leukemia development. MDS typically occur in elderly people, with a median age at diagnosis ranging between 60 and 75 years. The patients' prognosis, estimated according to the International Prognostic Scoring System, age and performance status should be considered before choosing among the various treatment options. A therapeutic dilemma exists in MDS, due to the multifactorial pathogenetic features of the disease, the heterogeneous stage and the elderly age of patients at diagnosis. This is underlined by the absence of a Food and Drug Administration-approved agent with an indication for this disease. The therapeutic end-points vary from symptom management (using low-intensity treatment with biological targeted agents, or only supportive therapy), to attempts to change the natural history of the disease (generally using high intensity treatment, including intensive chemotherapy and hemopoietic stem cell transplantation). The main goal of low-intensity therapies is generally to induce hematological improvements and is mainly used for low-risk disease. On the other hand, high-intensity therapies generally aims to alter the disease's natural history (improving survival, and decrease progression to acute myeloid leukemia), and are mainly used for high-risk disease. This review will focus on the current role of low-dose Ara-C therapy in the management of MDS. In fact, there is evidence that low-dose chemotherapy with Ara-C can induce responses in patients with MDS. In particular, the use in combinations with growth factors, such as G-CSF or M-CSF, looks promising, suggesting further investigations about this old new therapeutic tool.


  • No Preferential Sensitivity of t(8;21) Acute Myeloid Leukemias to Cytosine Arabinoside in Vitro: Is Intensity of Therapy or High Dose Ara-C Crucial for Response?

    by Giuseppe Visani, Alessandro Isidori, Tiziana Grafone, Patrizia Tosi, Valeria Santini, Michele Malagola, Giovanni Martinelli, Pier Paolo Piccaluga, Djavid Gaziev, Emanuela Ottaviani, et al.

    Acute myeloid leukemia (AML) patients with core binding factor abnormalities [inv(16) or t(8;21)] have a relatively good prognosis, especially patients with inv(16) when treated with high-dose cytosine arabinoside (AraC) containing regimens, whereas in the case of t(8;21) evidences in favor of such regimen are contrasting. We previously demonstrated that blast cells from inv(16)-positive AML patients are characterized by an increased sensitivity to AraC with higher incorporation of 3H AraC into DNA and the increase of induced apoptosis in vitro. In the present study we tested the sensitivity of leukemic cells from 15 t(8;21)-positive AML patients to AraC and compared it with the results obtained from cells of 74 patients with inv(16), "intermediate" or "unfavourable" karyotype at diagnosis (for a total of 89 patients). The incorporation of 3H AraC into DNA in cells with t(8;21) was significantly lower than in cells with inv(16) (P = 0.02) or normal karyotype (P = 0.04). Interestingly, the incorporation of the drug into DNA in t(8;21) cells was similar to those with "unfavourable" karyotype. Furthermore, AraC induced apoptosis in t(8;21)-positive AML cells was not increased. These data suggest that the mechanism of response to chemotherapy for t(8;21)-positive cells is probably different then in AML cells with inv(16), underlining the possible importance for patients carrying the t(8;21) of repeated high-dose regimens and not necessarily of high-dose AraC based ones.


    • 1 April 2004
      • Vol. 89  (4) , 495-7

    Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.

    by Giovanni Martinelli, Michela Rondoni, Silvia Buonamici, Emanuela Ottaviani, Pier Paolo Piccaluga, Michele Malagola, Michele Baccarani

    Many patients with the inv(16) positive acute myeloid leukemia (AML) achieve complete remission (CR). Using real-time reverse transcriptase polymerase chain reaction (RT-PCR), we previously proposed critical CBFbeta-MYH11 transcript copy number thresholds to predict relapse or cure. We now update the molecular follow-up of our patients, also presenting the therapeutic management of these patients.


  • Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation

    by Pier Paolo Piccaluga, Giovanni Martinelli, Michele Malagola, Michela Rondoni, Michele Bianchini, Ernesto Vigna, Costanza Bosi, Stavroula Gaitani, Giuseppe Visani, Michele Baccarani

    Despite aggressive approaches, including second transplant, donor lymphocyte infusion and several new agents, the prognosis of acute lymphoid leukemia (ALL) patients relapsing after stem-cell transplantation (SCT) remains poor. Monoclonal-antibodies (moAb) could provide a useful tool in this setting. In particular, anti-CD52 moAb is useful in lymphoid malignancies. We thus treated as compassionate with campath-1H 3 ALL patients relapsed after SCT. In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL.


  • Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

    by Pier Paolo Piccaluga, Michele Malagola, Michela Rondoni, Marilina Amabile, Stefania Paolini, Simona Soverini, Stavroula Gaitani, Giuseppe Visani, Michele Baccarani, Giovanni Martinelli


  • Prompt Resolution of Nasal Aspergillosis with Intra-Nasal Instillation of Liposomal Amphotericin-B (Ambisome®) and Granulocyte Transfusions

    by Pier Paolo Piccaluga, Paolo Ricci, Giovanni Martinelli, Michele Malagola, Michela Rondoni, Giuseppe Visani


    • 1 February 2004
      • Vol. 89  (2) , 236-7

    Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

    by Giovanni Martinelli, Michele Malagola, Emanuela Ottaviani, Gianantonio Rosti, Elena Trabacchi, Michele Baccarani


    • 1 December 2003
      • Vol. 88  (12) , ECR37

    Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.

    by Pier Paolo Piccaluga, Giovanni Martinelli, Michela Rondoni, Michele Malagola, Sonia Ronconi, Giuseppe Visani, Michele Baccarani

    • 1 November 2003
      • Vol. 88  (11) , 1221-8

    Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.

    by Giovanni Martinelli, Emanuela Ottaviani, Silvia Buonamici, Alessandro Isidori, Gabriela Borsaru, Giuseppe Visani, Pier Paolo Piccaluga, Michele Malagola, Nicoletta Testoni, Michela Rondoni, et al.

    Patients with acute myeloblastic leukemia (AML) with features of myelodysplastic syndrome and abnormalities of megakaryocytopoiesis often have cytogenetic aberrations of 3q21 and 3q26 bands involving the paracentric inversion [inv(3) (q21q26)] or a reciprocal translocation [t(3;3) (q21;q26)]. These abnormalities frequently cause inappropriate expression of the EVI1 gene located at 3q26. Other genes that have been implicated at the rearrangement breakpoint are GR6 and RPN1 (both on 3q21). The aim of this study was to investigate the expression of the EVI1 fusion genes in AML patients with 3q21q26 syndrome. We used reverse transcription polymerase chain reaction to evaluate the expression of EVI1 and GR6, and particularly of the fusion genes RPN1-EVI1 and GR6-EVI1 in 9 AML patients with either inv(3)(q21q26) (7 cases) or t(3;3)(q21;q26) (2 cases). EVI1 and GR6 were always expressed, as was RPN1-EVI1; GR6-EVI1 was absent. In 8/9 patients, the part of EVI1 retained in RPN1-DEVI1 contained blocks B and C of the PR domain commonly found in the MDS1-EVI1 gene. In the remaining patient [with inv(3) (q21q26)], only block C was retained: we named this variant fusion gene RPN1-DEVI1. This patient lacked the micromegakaryocytopoiesis frequently found in 3q21q26 syndrome. These findings support the hypothesis that EVI1 activation plays a dominant role in the pathogenesis of the 3q21q26 syndrome. EVI1 expression might occur either as a consequence of rearrangements leading to the formation of different fusion transcripts, such as RPN1-EVI1 and RPN1-DEVI1 or following disruption of the PR activation domain of the MDS1-EVI1 gene.